About: Custirsen

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Custirsen, aliases including custirsen sodium, OGX-011, and CC-8490, is an investigational drug that was under clinical testing for the treatment of cancer. It is an antisense oligonucleotide (ASO) targeting clusterin expression. In metastatic prostate cancer, custirsen showed no benefit in improving over all survival. Custirsen was developed through a collaboration of OncoGenex Pharmaceuticals Inc. and Isis. In 2009, OncoGenex Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd agreed to develop and commercialise Custirsen.

thumbnail
Property Value
dbo:abstract
  • Custirsen, aliases including custirsen sodium, OGX-011, and CC-8490, is an investigational drug that was under clinical testing for the treatment of cancer. It is an antisense oligonucleotide (ASO) targeting clusterin expression. In metastatic prostate cancer, custirsen showed no benefit in improving over all survival. Custirsen was developed through a collaboration of OncoGenex Pharmaceuticals Inc. and Isis. In 2009, OncoGenex Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd agreed to develop and commercialise Custirsen. (en)
dbo:casNumber
  • 890056-27-6
dbo:chemicalFormula
  • C231H312N78O119P20S20
dbo:drugbank
  • DB05487
dbo:fdaUniiCode
  • L26E95NLRK
dbo:thumbnail
dbo:wikiPageID
  • 60696171 (xsd:integer)
dbo:wikiPageLength
  • 11255 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1088460965 (xsd:integer)
dbo:wikiPageWikiLink
dbp:casNumber
  • 890056 (xsd:integer)
dbp:chemicalFormula
  • C231H312N78O119P20S20 (en)
dbp:chemspiderid
  • 34983386 (xsd:integer)
dbp:drugName
  • Custirsen (en)
dbp:drugbank
  • DB05487 (en)
dbp:synonyms
  • OGX-011, CC-8490 (en)
dbp:unii
  • L26E95NLRK (en)
dbp:wikiPageUsesTemplate
dcterms:subject
rdf:type
rdfs:comment
  • Custirsen, aliases including custirsen sodium, OGX-011, and CC-8490, is an investigational drug that was under clinical testing for the treatment of cancer. It is an antisense oligonucleotide (ASO) targeting clusterin expression. In metastatic prostate cancer, custirsen showed no benefit in improving over all survival. Custirsen was developed through a collaboration of OncoGenex Pharmaceuticals Inc. and Isis. In 2009, OncoGenex Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd agreed to develop and commercialise Custirsen. (en)
rdfs:label
  • Custirsen (en)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
foaf:name
  • Custirsen (en)
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License